Sample distribution of cluster-model healthy controls vs. patients with colorectal carcinoma (CA).

<p>The specificity above 85% point and the maximum Youden index point meet at a point 0.84 (Red line).</p

Workflow from gene screening, through gene selection, to experimental identification of a disease predictor.

<p>Workflow from gene screening, through gene selection, to experimental identification of a disease predictor.</p

ROC analysis and AUC of cluster-model Healthy-CA.

<p>A. Case processing summary specifying valid sample numbers and labels. B. Receiver operating characteristic (ROC) curve analysis for the cluster-model Healthy-CA. C. Test Result Variable (s) of the computed Y ~ BAD+11 x NEK6-48 model all including area under the curve, standard error; asymptotic significance (and asymptotic 95% confidence interval. C.^a. under the nonparametric assumption. C.^b. null hypothesis: true area = 0.5.</p

Sample distribution of cluster-model healthy controls vs. patient with advanced adenoma (AA).

<p>The specificity above 85% point and the maximum Youden index point meet at a point 2 (red line).</p

Clinical and histological data of study cohort.

<p>Clinical and histological data of study cohort.</p

Numbers of common genes between Affymetrix arrays and gene lists and number of genes used for the different steps of qPCR selections.

<p>Numbers of common genes between Affymetrix arrays and gene lists and number of genes used for the different steps of qPCR selections.</p

Published studies on the frequency of the MSI or MMR-defective phenotype in Pancreatic Ductal Adenocarcinoma.

*<p>Tumor specimens passed through xeno-transplantation of PDAC, unspecified whether consecutively collected.</p>#<p>By genomic DNA analysis for mutations.</p>§<p>Medullary cancers selected out of 450 randomly chosen PDAC.</p><p>“One patient with positive Bethesda criteria but negative <i>hMLH1</i> mutational analysis.</p><p>°3 PDAC arising in LS patients added to a series of 100 patients, unspecified whether consecutive.</p>∧<p>Long survivors (≥3 years) selected out of 373 PDAC patients.</p

Sequences of the primers employed for <i>BRAF^V600E</i> analysis.

<p>Sequences of the primers employed for <i>BRAF^V600E</i> analysis.</p

Patient demographics and survival, family history of gastrointestinal cancer, tumor pathological and molecular features, in 338 consecutively resected PDAC.

*<p>Including stomach, colon and pancreatic cancer in first degree relatives.</p><p>°Reported as G4 with respect to Tumor Grade.</p